^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    denikitug (GS-1811)

    i
    Other names: GS-1811, JTX-1811, GS1811, JTX1811, GS 1811, JTX 1811
    Associations

    News

    Trials
    Company:
    Gilead
    Drug class:
    CCR8 inhibitor
    Related drugs:
    Associations

    News

    Trials
    19d
    Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Gilead Sciences
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • HER-2 negative
    |
    Opdivo (nivolumab) • paclitaxel • Cyramza (ramucirumab) • denikitug (GS-1811)
    29d
    Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer (clinicaltrials.gov)
    P2, N=170, Not yet recruiting, Gilead Sciences
    New P2 trial
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • denikitug (GS-1811)
    10ms
    Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=416, Recruiting, Gilead Sciences | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2027 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    Yutuo (zimberelimab) • denikitug (GS-1811)
    2years
    Study of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=376, Recruiting, Gilead Sciences | N=216 --> 376 | Trial completion date: Feb 2027 --> Dec 2027 | Trial primary completion date: Jun 2026 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Yutuo (zimberelimab) • denikitug (GS-1811)
    almost3years
    Study of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=216, Recruiting, Gilead Sciences | N=158 --> 216 | Trial completion date: Feb 2025 --> Feb 2027 | Trial primary completion date: Feb 2024 --> Jun 2026
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Yutuo (zimberelimab) • denikitug (GS-1811)